The read at a glance
Computed from the FY2025 annual filing. Full history and the components behind each score are in the app.
- Distress risk · Altman Z-Score -2.63 — distress zone — historically elevated failure riskWatch
- Earnings-manipulation signal · Beneish M -2.19 — no flag raisedOK
- Earnings quality 100/100 — accruals in line with cashOK
Where the revenue comes from
Fiscal 2025, as BIOCRYST PHARMACEUTICALS INC reports it. History and quarterly detail are in the app.
- Product sales, net$623.2M
- ORLADEYO$601.8M
- License and other revenues$251.7M
- Other revenues$29.0M
- RAPIVAB$12.2M
Leadership changes
From BIOCRYST PHARMACEUTICALS INC's own filings, the day they're filed.
- Jon Stonehouse · Chief Executive Officer · departureeff. 2025-12-31
- Vincent J. Milano · departureeff. 2025-12-09
- Charlie Gayer · President · appointmenteff. 2025-08-01
Latest filings
- 8-K · Company announcement2026-06-29
- 8-K · Company announcement2026-06-12
- 10-Q · Quarterly report2026-05-06
- 8-K · Company announcement2026-05-06
- 8-K · Company announcement2026-05-04
In the full recordFree for 14 days
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, every figure source-linked🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask anything about BIOCRYST PHARMACEUTICALS INC, every answer cited🔒
- The Intelligence Brief — added when BIOCRYST PHARMACEUTICALS INC's brief passes our SEC-figure check🔒
Every figure links to the filing it came from, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.